title: Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
abstract: Targeted therapy and immunotherapy in metastatic melanoma have led to a marked improvement in patients' survival and their quality of life. Although there are data on anti-programmed-death-receptor-1 (anti-PD1) after ipilimumab, only few data are available on ipilimumab following anti-PD1 as the first-line treatment. The aim of our study was to evaluate tolerance and survival of patients treated with ipilimumab as the second-line immunotherapy among metastatic melanoma patients following anti-PD1 treatment. Retrospective and descriptive epidemiological studies were carried out at the Dermatology Department of the University Hospital of Lille. We describe a case series of patients treated with ipilimumab after anti-PD1 failure for metastatic melanomas. For each patient, we assessed disease extension since ipilimumab introduction using RECIST 1.1. The time between ipilimumab introduction and other systemic treatment and overall survival (between ipilimumab introduction and last patient visit) was assessed. The effect of ipilimumab after anti-PD1 treatment was evaluated in eight patients. Four patients responded to ipilimumab: three showed a complete response and one showed a partial response. For these patients, the time period between the first ipilimumab injection and another systemic treatment ranged from 209 to 391 days and the overall survival ranged from 314 to 581 days. One patient showed grade 3 chorioretinitis, an unusual toxicity with ipilimumab or anti-PD1 to our knowledge. We have described the efficacy of ipilimumab following anti-PD1 in metastatic melanoma in eight patients. Several comparative studies are still in progress, and their results will be important to develop an optimal therapeutic strategy for our patients.
authors.affiliation: aDermatology Department, Claude Huriez Hospital, CHRU Lille, Lille bInfectious Disease Unit, Pavillon Fourrier, CHRU de Lille, Lille cModern Languages Department, Ecole Centrale de Lille, Villeneuve d'Ascq, France.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Jacobsoone-Ulrich
authors.forename: Philippe
authors.initials: P
authors.lastname: Jamme
authors.forename: Salim
authors.initials: S
authors.lastname: Alkeraye
authors.forename: Véronique
authors.initials: V
authors.lastname: Dzwiniel
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Faure
authors.forename: Carole
authors.initials: C
authors.lastname: Templier
authors.forename: Laurent
authors.initials: L
authors.lastname: Mortier
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007167:Immunotherapy; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor